New pill targets multiple KRAS mutations in Hard-to-Treat cancers

NCT ID NCT06607185

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The drug is given alone or combined with other cancer treatments to first check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4066434 (a Pan-KRAS inhibitor drug taken by mouth)
What this could lead to: If this drug is safe and shows promise, it could lead to a new treatment option for several cancers driven by KRAS mutations, such as pancreatic, lung, and colorectal cancer.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will work. Side effects are unknown, and the drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma colonic neoplasm colorectal cancer colorectal neoplasm endometrium neoplasm Esophageal Neoplasms lung neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer pancreatic ductal adenocarcinoma pancreatic neoplasm rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR COLORECTAL CANCER METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCER PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Asklepios Kliniken Hamburg GmbH - Asklepios Klinik Altona

Hamburg, 22763, Germany
Cancer Institute Hospital of JFCR

Tokyo, 135-8550, Japan
Centre Leon Berard

Lyon, 69373, France
Centro Ricerche Cliniche di Verona s.r.l.

Verona, 37134, Italy
City of Hope

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Cliniques universitaires Saint-Luc

Brussels, 1200, Belgium
Columbia University

New York, New York, 10032, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Hospital General Universitario Gregorio Maranon

Madrid, 28007, Spain
Hospital Regional Universitario de Malaga

Málaga, 29010, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Hospital del Mar

Barcelona, 08003, Spain
Indiana University (IU)

Indianapolis, Indiana, 46202, United States
Institut Catala d'Oncologia - L'Hospitalet

Barcelona, 08908, Spain
Krankenhaus Nordwest GmbH

Frankfurt, 60488, Germany
Kyoto University Hospital

Kyoto, 606-8507, Japan
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Phoenix, Arizona, 85054, United States
National Cancer Center Hospital

Tokyo, 104-0045, Japan
National Cancer Center Hospital East

Chiba, 277-8577, Japan
National Taiwan University Hospital

Taipei, 10016, Taiwan
National Taiwan University Hospital Hsin-Chu Branch

Hsinchu, 300195, Taiwan
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
SLK-Kliniken Heilbronn GmBH

Heilbronn, 74078, Germany
Sarah Cannon Research Institute/SCRI

Nashville, Tennessee, 37203, United States
Shizuoka Cancer Center

Shizuoka, 411-8777, Japan
South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, 78229, United States
South Texas Accelerated Research Therapeutics (START) Midwest

Grand Rapids, Michigan, 49546, United States
Swedish Cancer Institute (SCI)

Seattle, Washington, 98104, United States
The University of Chicago Medical Center (UCMC)

Chicago, Illinois, 60637, United States
UZ Gent

Ghent, 9000, Belgium
Universitaetsklinikum Wuerzburg

Würzburg, 97080, Germany
Universite Libre de Bruxelles (ULB) - Institut Jules Bordet

Brussels, 1070, Belgium
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of California, Los Angeles (UCLA)

Santa Monica, California, 90404, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States
University of Texas Southwestern

Dallas, Texas, 75244, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States
Yale University School of Medicine - Yale Cancer Center

New Haven, Connecticut, 06520-8028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.